RET and medullary thyroid gland carcinoma: Currently, we have no statistically significant data to pinpoint whether MEN2-CLA should be approached differently than non-MTC cases and whether LCA in association with a thyroid malignancy/neuroendocrine neoplasm is more severe apart from an increased disease burden that comes with the clinical expression due to the RET pathogenic variants.